ReviewESMO open2020
New emerging targets in cancer immunotherapy: the role of neoantigens.
Review in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Pooled it
- Development of a multi-neoepitope vaccine targeting non-small cell lung cancer through reverse vaccinology and bioinformatics approaches.Frontiers in immunology · 2025Article
- DNA Vaccines: Their Formulations, Engineering and Delivery.Vaccines · 2024Review
- Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.Journal of translational medicine · 2024Article
- Neoantigen-directed therapeutics in the clinic: where are we?Trends in cancer · 2023Review
- Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.Cellular and molecular neurobiology · 2023Article
- Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments.Cancers · 2022Review
- A synthetic DNA template for fast manufacturing of versatile single epitope mRNA.Molecular therapy. Nucleic acids · 2022Article
- Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.Journal for immunotherapy of cancer · 2022Article
- Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.Life (Basel, Switzerland) · 2022Review
- Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle.Therapeutic advances in medical oncology · 2022Review
- Neoantigens and NK Cells: "Trick or Treat" the Cancers?Frontiers in immunology · 2022Review
- Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy.Frontiers in immunology · 2022Article
- Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy.Annals of translational medicine · 2021Review
- Article
- The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ breast cancer · 2021Article
- A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer.Translational cancer research · 2021Article
- The Role of Neoantigens in Cancer Immunotherapy.Frontiers in oncology · 2021Review
- VISTA: A Promising Target for Cancer Immunotherapy?ImmunoTargets and therapy · 2021Review
- Neo-Antigen mRNA Vaccines.Vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of cancer therapies with immune checkpoint inhibitors is transforming the treatment of patients with cancer and fostering cancer research. Therapies that target immune checkpoint inhibitors have shown unprecedented rates of durable long-lasting responses in patients with various cancer types, but only in a fraction of patients. Thus, novel approaches are needed to make immunotherapy more precise and also less toxic. The advances of next-generation sequencing technologies have allowed fast detection of somatic mutations in genes present in the exome of an individual tumour. Targeting neoantigens, the mutated peptides expressed only by tumour cells, may enable antitumour T-cell responses and tumour destruction without causing harm to healthy tissues. Currently, neoantigens can be identified in tumour clinical samples by using genomic-based computational tools. The two main treatment modalities targeting neoantigens that have been investigated in clinical trials are personalised vaccines and tumour infiltrating lymphocytes-based adoptive T-cell therapy. In this mini review, we discuss the promises and challenges for using neoantigens as emergent targets to personalise and guide cancer immunotherapy in a broader set of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.